Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mebeverine+Simethicone FDC in Functional Bowel Disorders
NCT05175131Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in functional bowel disorder (FBD) comparing Mebeverine+Simethicone combination, Mebeverine and Simethicone (3 arms). Primary endpoint: Change From Baseline of Sum of NRS-11 Abdominal Pain and Bloating/Flatulence Intensity Scores at 4 weeks. Started Nov 2020; status: completed.
02
Drugs
mebeverinesimethicone
03
Conditions
functional bowel disorder (FBD)
Beyond the preview
Go deeper on NCT05175131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05175131.